WO2010078370A1 - Synthesis of 18f-radiolabeled styrylpyridines from tosylate precursors and stable pharmaceutical compositions thereof - Google Patents
Synthesis of 18f-radiolabeled styrylpyridines from tosylate precursors and stable pharmaceutical compositions thereof Download PDFInfo
- Publication number
- WO2010078370A1 WO2010078370A1 PCT/US2009/069741 US2009069741W WO2010078370A1 WO 2010078370 A1 WO2010078370 A1 WO 2010078370A1 US 2009069741 W US2009069741 W US 2009069741W WO 2010078370 A1 WO2010078370 A1 WO 2010078370A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- radiopharmaceutical composition
- radiopharmaceutical
- ethoxy
- radiolabeled
- composition
- Prior art date
Links
- 239000002243 precursor Substances 0.000 title claims abstract description 32
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 title claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 10
- 238000003786 synthesis reaction Methods 0.000 title claims description 21
- 230000015572 biosynthetic process Effects 0.000 title description 16
- 238000000034 method Methods 0.000 claims abstract description 40
- BIAWAXVRXKIUQB-UHFFFAOYSA-N 2-(2-phenylethenyl)pyridine Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=N1 BIAWAXVRXKIUQB-UHFFFAOYSA-N 0.000 claims abstract description 10
- 230000002194 synthesizing effect Effects 0.000 claims abstract description 5
- 239000012217 radiopharmaceutical Substances 0.000 claims description 85
- 229940121896 radiopharmaceutical Drugs 0.000 claims description 85
- 230000002799 radiopharmaceutical effect Effects 0.000 claims description 84
- 239000000203 mixture Substances 0.000 claims description 81
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 76
- 150000001875 compounds Chemical class 0.000 claims description 40
- 235000019441 ethanol Nutrition 0.000 claims description 31
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 30
- 235000010378 sodium ascorbate Nutrition 0.000 claims description 28
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims description 28
- 229960005055 sodium ascorbate Drugs 0.000 claims description 28
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 claims description 28
- 210000004556 brain Anatomy 0.000 claims description 23
- 238000002600 positron emission tomography Methods 0.000 claims description 22
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 20
- 238000003384 imaging method Methods 0.000 claims description 19
- 208000018737 Parkinson disease Diseases 0.000 claims description 17
- -1 mono Boc-protected vinylaniline compound Chemical class 0.000 claims description 17
- 230000004770 neurodegeneration Effects 0.000 claims description 17
- 208000024827 Alzheimer disease Diseases 0.000 claims description 16
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 16
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 15
- 201000002832 Lewy body dementia Diseases 0.000 claims description 15
- 229920002554 vinyl polymer Polymers 0.000 claims description 14
- 208000037259 Amyloid Plaque Diseases 0.000 claims description 13
- 206010012289 Dementia Diseases 0.000 claims description 11
- 150000000994 L-ascorbates Chemical class 0.000 claims description 10
- 201000004810 Vascular dementia Diseases 0.000 claims description 10
- 235000010323 ascorbic acid Nutrition 0.000 claims description 10
- 239000011668 ascorbic acid Substances 0.000 claims description 10
- 229960005070 ascorbic acid Drugs 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 10
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 9
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 9
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 9
- YNDIAUKFXKEXSV-CRYLGTRXSA-N florbetapir F-18 Chemical compound C1=CC(NC)=CC=C1\C=C\C1=CC=C(OCCOCCOCC[18F])N=C1 YNDIAUKFXKEXSV-CRYLGTRXSA-N 0.000 claims description 9
- 230000001575 pathological effect Effects 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 102000009659 Vesicular Monoamine Transport Proteins Human genes 0.000 claims description 6
- 108010020033 Vesicular Monoamine Transport Proteins Proteins 0.000 claims description 6
- 102000003802 alpha-Synuclein Human genes 0.000 claims description 6
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 230000002159 abnormal effect Effects 0.000 claims description 5
- 239000000010 aprotic solvent Substances 0.000 claims description 5
- 238000009835 boiling Methods 0.000 claims description 5
- 238000003745 diagnosis Methods 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 claims description 5
- 208000010877 cognitive disease Diseases 0.000 claims description 4
- 150000002081 enamines Chemical class 0.000 claims description 4
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical class CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 claims description 4
- XDELKSRGBLWMBA-UHFFFAOYSA-N 3-iodopyridine Chemical compound IC1=CC=CN=C1 XDELKSRGBLWMBA-UHFFFAOYSA-N 0.000 claims description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
- 208000028698 Cognitive impairment Diseases 0.000 claims description 3
- 108091034117 Oligonucleotide Proteins 0.000 claims description 3
- 238000013170 computed tomography imaging Methods 0.000 claims description 3
- 125000001475 halogen functional group Chemical group 0.000 claims description 3
- 230000000269 nucleophilic effect Effects 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000005504 styryl group Chemical group 0.000 claims description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 4
- GNKGXQHHUUEYQV-WTHAECTESA-N florbenazine (18f) Chemical compound C([C@@H]12)[C@@H](O)[C@H](CC(C)C)CN1CCC1=C2C=C(OC)C(OCCC[18F])=C1 GNKGXQHHUUEYQV-WTHAECTESA-N 0.000 claims 1
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- 239000000243 solution Substances 0.000 description 20
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 229940126534 drug product Drugs 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000000825 pharmaceutical preparation Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000000354 decomposition reaction Methods 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000012216 imaging agent Substances 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 238000001308 synthesis method Methods 0.000 description 6
- WEQLWGNDNRARGE-DJIMGWMZSA-N (2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-ol Chemical compound C1CN2C[C@@H](CC(C)C)[C@H](O)C[C@@H]2C2=C1C=C(OC)C(OC)=C2 WEQLWGNDNRARGE-DJIMGWMZSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 230000002285 radioactive effect Effects 0.000 description 5
- 238000003608 radiolysis reaction Methods 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000000032 diagnostic agent Substances 0.000 description 4
- 229940039227 diagnostic agent Drugs 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 210000004558 lewy body Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000002610 neuroimaging Methods 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- SCWKRWCUMCMVPW-UHFFFAOYSA-N phenyl n-methylcarbamate Chemical compound CNC(=O)OC1=CC=CC=C1 SCWKRWCUMCMVPW-UHFFFAOYSA-N 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000005063 solubilization Methods 0.000 description 4
- 230000007928 solubilization Effects 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000011888 autopsy Methods 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 125000006005 fluoroethoxy group Chemical group 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000005258 radioactive decay Effects 0.000 description 3
- 239000000700 radioactive tracer Substances 0.000 description 3
- 238000007070 tosylation reaction Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- LLKRSJVPTKFSLS-UHFFFAOYSA-N 2-bromo-5-iodopyridine Chemical compound BrC1=CC=C(I)C=N1 LLKRSJVPTKFSLS-UHFFFAOYSA-N 0.000 description 2
- 208000003808 Amyloid Neuropathies Diseases 0.000 description 2
- 238000007341 Heck reaction Methods 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 206010002022 amyloidosis Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000002144 chemical decomposition reaction Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 210000005064 dopaminergic neuron Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000003682 fluorination reaction Methods 0.000 description 2
- KRHYYFGTRYWZRS-BJUDXGSMSA-M fluorine-18(1-) Chemical compound [18F-] KRHYYFGTRYWZRS-BJUDXGSMSA-M 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- CKFGINPQOCXMAZ-UHFFFAOYSA-N methanediol Chemical compound OCO CKFGINPQOCXMAZ-UHFFFAOYSA-N 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- PZUGJLOCXUNFLM-UHFFFAOYSA-N n-ethenylaniline Chemical compound C=CNC1=CC=CC=C1 PZUGJLOCXUNFLM-UHFFFAOYSA-N 0.000 description 2
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 238000000163 radioactive labelling Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000008354 sodium chloride injection Substances 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 210000003523 substantia nigra Anatomy 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 2
- 125000005490 tosylate group Chemical group 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- BWZHKRSSCFRVIE-UHFFFAOYSA-N 1-n,4-n-dimethyl-2h-pyridine-1,4-diamine Chemical compound CNN1CC=C(NC)C=C1 BWZHKRSSCFRVIE-UHFFFAOYSA-N 0.000 description 1
- NYCKOPKJAVKWAT-UHFFFAOYSA-N 2-[2-[2-(5-iodopyridin-2-yl)oxyethoxy]ethoxy]ethanol Chemical compound OCCOCCOCCOC1=CC=C(I)C=N1 NYCKOPKJAVKWAT-UHFFFAOYSA-N 0.000 description 1
- CCZWSTFVHJPCEM-UHFFFAOYSA-N 2-iodopyridine Chemical compound IC1=CC=CC=N1 CCZWSTFVHJPCEM-UHFFFAOYSA-N 0.000 description 1
- HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- BRZRLZJBQXNWKK-UHFFFAOYSA-N C1=CC(N(C(O)=O)C)=CC=C1C=CC1=CC=C(OCCOCCOCCO)N=C1 Chemical compound C1=CC(N(C(O)=O)C)=CC=C1C=CC1=CC=C(OCCOCCOCCO)N=C1 BRZRLZJBQXNWKK-UHFFFAOYSA-N 0.000 description 1
- 206010007509 Cardiac amyloidosis Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 201000002795 Muckle-Wells syndrome Diseases 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000005821 brain abnormality Effects 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- KPMVHELZNRNSMN-UHFFFAOYSA-N chembl1985849 Chemical compound N1=CC=C2NCCN21 KPMVHELZNRNSMN-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000007819 coupling partner Substances 0.000 description 1
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical compound OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000006739 dopaminergic cell death Effects 0.000 description 1
- 230000004771 dopaminergic neurodegeneration Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- VRZVPALEJCLXPR-UHFFFAOYSA-N ethyl 4-methylbenzenesulfonate Chemical compound CCOS(=O)(=O)C1=CC=C(C)C=C1 VRZVPALEJCLXPR-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000019256 formaldehyde Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 201000008319 inclusion body myositis Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022498 insulinoma Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 206010023497 kuru Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000000627 locus coeruleus Anatomy 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical group CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 125000002577 pseudohalo group Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 208000008864 scrapie Diseases 0.000 description 1
- 238000011894 semi-preparative HPLC Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-N tert-butylcarbamic acid Chemical compound CC(C)(C)NC(O)=O XBXCNNQPRYLIDE-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0069—Devices for implanting pellets, e.g. markers or solid medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- the present invention relates generally to synthesis methods for 18 F- radiolabeled brain imaging agents and more specifically to methods of synthesizing 18 F- radiolabeled styrylpyridine and its tosylale precursor and to stable pharmaceutical compositions comprising 18 F-radiolabeled brain imaging agents.
- AD Alzheimer's Disease
- cognitive decline characterized by cognitive decline, irreversible memory loss, disorientation, and language impairment.
- AD affects 10% of the population aged greater than 65 and at least 50% of the population aged greater than 85 years.
- AD has been reported in patients as young as 40-50 years of age, but because the presence of the disease is difficult to detect without histopathological examination of brain tissue, the time of onset in living subjects is unknown.
- NPs neuritic plaques
- NFTs neurofibrillary tangles
- the amyloid deposits are fo ⁇ ned by aggregation of amyloid peptides, followed by further combination with other aggregates and/or amyloid peptides.
- the fibrillar aggregates of amyloid peptides, A ⁇ l -40 and Ap 1-42 are the major peptide metabolites derived from amyloid precursor protein that are found in NPs and cerebrovascular amyloid deposits in AD patients.
- Parkinson's Disease is a progressive neurodegenerative disease characterized by resting tremors, bradykinesia, muscular rigidity, and postural instability. PD typically develops after the age of 60, though 15% of diagnosed patients are under the age of 50. Family history of PD is an etiological factor for 5-10% of patients diagnosed with the disease, yet only 1% of cases have been shown to be clearly familial. It is estimated that 1.5 million Americans are currently living with PD.
- Dementia with Le ⁇ vy Bodies (DLB) is a progressive brain disease having symptoms that fluctuate between various degrees of manifestation. These symptoms include progressive dementia, Parkinsonian movement difficulties, hallucinations, and increased sensitivity to neuroleptic drugs.
- AD 1 advanced age is considered to be the greatest risk factor for DLB, with average onset usually between the ages of 50-85. Further, 20% of all dementia cases are caused by DLB and over 50% of PD patients develop "Parkinson's Disease Dementia” (PDD), a type of DLB. It is possible for DLB to occur alone, or in conjunction with other brain abnormalities, including those involved in AD and PD, as mentioned above. At present, a conclusive diagnosis of DLB is only possible after postmortem autopsy.
- PDD Parkinson's Disease Dementia
- PD and DLB share an etiology of dopamine deficiency that is correlated with the death of dopaminergic neurons in the substantia nigra.
- the cause of dopaminergic neuronal death in PD is uncertain, although it appears that aggregates of ⁇ -synuclein in the brain may be associated with dopaminergic neuronal losses in the striatum. It is also recognized that in DLB, abnormal protein deposits containing ⁇ -synuclein, referred to as "Lewy bodies", are the cause of the death of dopaminergic neurons.
- Lewy bodies occur mostly in the substantia nigra and locus ceruleus sections of the brain stem, and also in the subcortical and cortical regions of the brain. Because of this particular localization in the brain, Lewy bodies may interfere with the production of acetylcholine, causing disruption of perception and thought process and impacting behavior. Lewy bodies are considered to be a type of neuritic plaque (NP) because they are comprised of aggregates of ⁇ -synuclein protein deposits.
- the etiology of neurodegeneration can also involve a mixture of pathologies including a component of microvascular, or perfusion, deficits in the brain.
- a disorder commonly referred to as “mixed dementia” often comprises both perfusion deficits and amyloid plaque pathology.
- the term “mixed dementia” possesses various meanings, but the te ⁇ n is commonly used to refer to the coexistence of AD and vascular dementia (VaD), in particular where the VaD is caused by numerous micro-thrombi in the vascular system of the brain.
- VaD vascular dementia
- this form of neurodegeneration is clinically important because the combination of AD and VaD may have a greater impact on the brain than either condition independently. Mixed dementia is traditionally very difficult to diagnose.
- amyloid deposits in the brain may be characterisiic of numerous other conditions including, but not limited to, Mediterranean fever, Muckle- Wells syndrome, idiopathetic myeloma, amyloid polyneuropathy, amyloid cardiomyopathy, systemic neuritic amyloidosis, amyloid polyneuropathy, hereditary cerebral hemorrhage with 5 amyloidosis, Down's syndrome, Scrapie, Creutzfeldt-Jacob disease, Kuru, Gerstamnn- Straussler-Scheinker syndrome, medullary carcinoma of the thyroid, isolated atrial amyloid, ⁇ 2-microglobulin amyloid in dialysis patients, inclusion body myositis, ⁇ >-amyloid deposits in muscle wasting disease, and islets of Langerhans diabetes Type II insulinoma.
- Some common imaging agents include ( 1 1 ClPlB, [ 1 1 C] 4-N-methylamino-4'-hydroxy-stilbene (SB- 13), [ 18 FIFDDNP and [ 123 I
- F]fluoroethoxy)ethoxy)ethoxy) pyridine-3-yl)vinyl)-iV-methylbenzenamine is a radiopharmaceutical for Positron Emission Tomography (PET) imaging of amyloid aggregates in the brain (see, for example, Choi, SR, et al., ./ Niicl Med, 50( 1 1), 1887- 1894, 2009).
- 18 F-AV- 45 contains the F- 18 radioisotope which, due to its 1 10 minute radioactive decay half life, may be manufactured in a centralized location and shipped within a 4 to 8 hour radius to imaging 0 centers that perform the PET brain imaging.
- the radioactive 18 F-A V-45 must be produced in a short period of time from a stable intermediate 5 compound (referred to as the "precursor"); second, the 18 F-A V-45 radiopharmaceutical must be produced in reasonable (e.g., >10%) radiochemical yield starting from the precursor reacting with F-18 fluoride ion; and third, the 18 F-AV-45 must be in a solution medium which provides adequate solubility of both the radiopharmaceutical as well as its non-radioactive counterpart ( 19 F-AV-45, which is always present at some low level due to stable F- 19 in the manufacturing 0 environment), as well as stabilization properties to inhibit the radiolytic breakdown of the compound.
- Ethanol is generally recognized as a suitable aid for solubilization of lipophilic drugs, including radiopharmaceutical drugs (see, for example, Lemaire C, et al., J Label Compd and Radiopharm, 42, 63-75, 1999). Ascorbic acid or ascorbate salts have been utilized previously as aids in inhibiting radiolysis of radiopharmaceuticals (see, for example, Tofe AJ, et al., ./.
- Embodiments of the invention are directed to a radiopharmaceutical composition for positron emission tomography (PET) imaging of neurodegenerative diseases of the brain comprising an effective amount of an ls F-radiolabeled compound, aboul 1.0% to about 20% (v/v) of ethyl alcohol, and at least aboul 0.1% (w/v) of ascorbic acid or a salt thereof.
- the l8 F-radioIabeled compound is capable of binding to a pathologic target in the brain of a patient.
- the pathologic target may include an abnormal concentration of a native or pathologically-altered protein, peptide or oligonucleotide; ⁇ - amyloid; ⁇ -synuclein; or vesicular monoamine transporter 2 (VMAT2).
- VMAT2 vesicular monoamine transporter 2
- the 18 F-radiolabeled compound is a styrylpyridine derivative.
- the 18 F-radiolabeled compound is ((£)-4-(2- (6-(2-(2-(2-
- the 18 F-A V-45 is produced from a tosylate precursor.
- the l8 F-radiolabeled compound in the radiopharmaceutical composition is (2/e,3 ⁇ ,l lb/?)-9-(3-
- the 18 F- radiolabeled compound is a derivative ofdihydrotetrabenazine (DTBZ).
- the radiopharmaceutical composition of some embodiments includes an ethyl alcohol concentration in the range of about 1.0% to about 15.0% (v/v). Other embodiments include a concentration of ascorbic acid or salt thereof in the range of about 0.1% Io about 1.0% (w/v).
- the pH of the radiopharmaceutical composition can range from about 4.5 to about 8.0. In preferred embodiments, the purity of the radiopharmaceutical composition is greater than or equal to about 90% when measured at least about 4 hours post end-of-synthesis (EOS).
- the radiopharmaceutical composition can be used in the diagnosis of neurodegenerative disease such as, for example, dementia, cognitive impairment, Alzheimer's Disease (AD), Parkinson's Disease (PD), Dementia with Lewy Bodies (DLB), Vascular Dementia (VaD) and combinations thereof.
- neurodegenerative disease such as, for example, dementia, cognitive impairment, Alzheimer's Disease (AD), Parkinson's Disease (PD), Dementia with Lewy Bodies (DLB), Vascular Dementia (VaD) and combinations thereof.
- Radiopharmaceutical composition for positron emission tomography (PET) imaging of the brain comprising an effective amount of an 18 F-radiolabeled compound, at least about 1.0% (v/v) of ethyl alcohol, and at least about 0.1% (w/v) of an ascorbate salt, wherein the ls F-radiolabeled compound decomposes less than about 10% from the end-of-synthesis to about 12 hours after the end- of-synlhesis.
- PET positron emission tomography
- a "method for diagnosing a neurodegenerative disease in a patient comprising the steps of administering a radiopharmaceutical composition capable of binding to a target associated with a neurodegenerative disease to a patient, wherein said radiopharmaceutical composition includes an effective amount of 18 F-radiolabeled compound, at least about 1.0% (v/v) of ethyl alcohol, and at least about 0.1 % (w/v) sodium ascorbate; imaging at least a portion of the patient's brain including a region wherein lhe target is expected to be positioned; and detecting the target.
- the imaging step may be performed using positron emission tomography (PET) imaging, PET with concurrent computed tomography imaging (PET/CT), PET with concurrent magnetic resonance imaging (PET/MR1) or a combination thereof.
- a method for producing an 18 F-radiolabeIed composition capable of binding to ⁇ -amyloid including the steps of synthesizing a tosylate precursor; performing nucleophilic 18 F fluorination of the tosylate precursor in a dimethylsulfoxide (DMSO) solution to provide an 18 F radiopharmaceutical; and formulating the 13 F radiopharmaceutical in an aqueous-ethyl alcohol solution containing ascorbic acid or a salt thereof; wherein the ethyl alcohol is present at a minimum concentration of about 1.0% (v/v) and the minimum concentration of the ascorbic acid or salt thereof is about 0.1% (w ⁇ ') in the final 18 F-radiolabeled pharmaceutical composition.
- DMSO dimethylsulfoxide
- AV-45 (/0-2-(2-(2-(5-(4-(/er/-butoxycarbonyl(melhyl)amino)styryl)pyridin-2-yloxy)ethoxy) etho ⁇ y)ethyl 4-methylbenxenesulfonate ("AV- 105"), is provided.
- This method includes the steps of (i) preparing a mono Boc-protected vinylaniline compound; (ii) converting the vinylaniline compound to a methyl, t-butyl carbamate derivative; (iii) reacting 2-halo 5- iodopyridine with triethyleneglycol; (iv) reacting the methyl, t-butyl carbamate derivative of step (ii) with the resultant compound of step (iii) to produce (/;)-te/7-Butyl 4-(2-(6-(2-(2-(2- hydroxyethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)phenyl(methyI)carbamate; and (v) reacting the (E)-terl-Buly ⁇ 4-(2-(6-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)pyridin-3- yl)vinyl)phenyl(methyl)carbamate with tosyl chloride to form
- a method of producing a radiopharmaceutical composition including reacting the AV- 105 tosylate precursor with an 18 F-fluoride ion in dimethylsulfoxide (DMSO) solution or other high- boiling point aprotic solvent to produce ((E)-4-(2-(6-(2-(2-(2- [ !8 F]fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methylbenzenamine) ( 18 F- AV-45); isolating the 18 F-A V-45; and purifying the 18 F-A V-45.
- DMSO dimethylsulfoxide
- the method of producing the radiopharmaceutical composition may further include the step of formulating the 18 F-AV-45 in a solution containing about 1.0% to about 15% (v/v) of ethyl alcohol and about 0.1% to about 1.0% (w/v) of an ascorbaie salt.
- the ascorbate salt is sodium ascorbate and (he concentration is about 0.5% (w/v).
- FIG. 1 shows a schematic of the synthesis of tosylate precursor AV-105 and the synthesis of non-radioactive 19 F-AV-45 from /Moluenesulfonate according to one embodiment of the invention
- FIG. 2 shows an alternative synthesis method for tosylate precursor AV-105 according to another embodiment of the invention.
- FIG. 3 depicts a radiosynthesis method of one aspect of the invention using a losylate precursor to produce ⁇ -amyloid binding radiopharmaceutical l8 F-AV-45.
- administering when used in conjunction with an diagnostic agent, such as, for example, a radiopharmaceutical, means to administer directly into or onto a target tissue or to administer the radiopharmaceutical systemically to a patient whereby the diagnostic agent is used to image the tissue or a pathology associated with the tissue to which it is targeted.
- administering a composition may be accomplished by injection, infusion, or by either method in combination with other known techniques.
- an "effective amount” or “therapeutically effective amount”, as used herein, refers to the amount of positron-emitting radiopharmaceutical that results in a sufficient gamma radiation signal to adequately image the biological target of interest in the brain of an individual with a suspected neurodegenerative disease.
- end-of synthesis means end-of- radiosynthesis. This is the timepoint at which the radiosynthesis process, including any purification steps required for isolation of the radiopharmaceutical, are completed.
- high-boiling point aprotic solvent is defined as an aprotic solvent having a boiling point of at least about 140 0 C at one (1) aim.
- pathology refers to an altered biological process that may be, for example, associated with aberrant production of proteins, peptides, RNA, and other substances associated with a disease process.
- patient and “subject” refer to any living organism to which the compounds described herein are administered and whose brain activity is to be measured in conjunction with performing the analysis methods of the invention.
- Patients and/or subjects may include, but are not limited to, any non-human mammal, primate or human. Such patients and/or subjects may or may not be exhibiting signs, symptoms or pathology of one or more particular diseased states.
- target when used in conjunction with a diagnostic agent, such as the radiopharmaceutical of the present invention, refers to tissue or other material associated with pathology to which localization of the radiopharmaceutical or diagnostic agent is desired.
- Targets may include, but are not limited to, diseased cells, pathogens, infectious material or other undesirable material in a patient, such as abnormal proteins, peptides, RNA or DNA or normally-expressed receptors that are altered in a disease process.
- tissue refers to any aggregation of similarly specialized cells that are united in the performance of a particular function.
- Various embodiments of the invention provide a method for the synthesis of an l8 F-radiolabeled imaging agent from a tosylale precursor and a pharmaceutical composition of a stable drug product comprising such 18 F-radiolabeled imaging agent.
- Certain embodiments of the invention are directed to a radiopharmaceutical composition
- a radiopharmaceutical composition comprising an effective amount of an 18 F-radiolabeled compound, such as an l8 F-radiolabeled styrylpyridine or an 1S F-Iabeled dihydrotetrabenazine (DTBZ) derivative, in a solution containing about 1.0% to about 30% (w/v) of ethyl alcohol, and at least about 0.1 % (w/v) sodium ascorbate.
- an 18 F-radiolabeled compound such as an l8 F-radiolabeled styrylpyridine or an 1S F-Iabeled dihydrotetrabenazine (DTBZ) derivative
- Radiopharmaceutical composition comprising an effective amount of an 18 F-radiolabeled compound in a solution for intravenous injection containing about 1.0% to about 20% (v/v) of ethyl alcohol, and at least about 0.1% (w/v) sodium ascorbate with a pH of between approximately 4.5 and 8.0.
- This radiopharmaceutical composition is a clear solution, without insoluble matter, which is stable for at least 6 hours following production at concentrations up to 100 mCi/mL (37 to 3700 MBq/mL) or more of the F-18 radiopharmaceutical.
- the parenteral radiopharmaceutical composition of embodiments of the invention may contain a F-18 radiolabeled compound which is capable of binding to a pathologic target in a brain of a patient such as, for example, an abnormal concentration of a native or pathologically-altered protein, peptide or oligonucleotide, ⁇ -amyloid, ⁇ -synuclein, or to a normally-expressed endogenous target that is impaired in the presence of certain degenerative disorders such as the vesicular monoamine transporter (VMAT2) in Parkinson's Disease (PD), Dementia with Lewy Bodies (DLB), or diabetes.
- VMAT2 vesicular monoamine transporter
- PD Parkinson's Disease
- DLB Dementia with Lewy Bodies
- Various embodimenis of the invention provide radiopharmaceutical compositions having characteristics including: a high affinity and selectivity for the target, low molecular weight ( ⁇ 400 g/mol), medium lipophilicty (log P in the range of 1 -3) to ensure high initial brain uptake with rapid clearance, functional groups in the molecule for introduction of positron emitting radionuclides such as, for example, "C or 18 F, high stability in the brain as well as no brain uptake of peripherally generated metabolites of the tracer compound, and high availability of the tracer compound for clinical centers.
- the relatively longer half-life of 18 F is advantageous in that more time is provided for clearance of non-specifically bound tracer with less loss of signal strength due to radioactive decay.
- the 18 F-radiolabeled compound in the radiopharmaceutical composition comprises an l8 F-radiolabeled compound, which is capable of binding to amyloid aggregates for use in positron emission tomography (PET) imaging of the brain.
- the l8 F-radiolabeled compound is ((/ ⁇ )-4-(2-(6-(2-(2- (2-f ls F
- the 18 F-A V-45 is produced from a tosylate precursor.
- the 1!i F-radiolabeled compound is a derivative of dihydrotetrabenazine (DTBZ).
- the 18 F-radiolabeled compound in the radiopharmaceutical composition is (2 ⁇ ,3/?,1 lb ⁇ )-9-(3-[ 18 F]Fluoropropoxy)-3-isopropyl-10- methoxy-1 lb-methyl-2,3,4,6,7,1 lb-hexahydro-lH-pyrido[2,l-cr
- a radiopharmaceutical composition comprising an effective amount of an l8 F-radiolabeled compound, at least about 1.0% (w/v) of ethyl alcohol, and at least about 0.1% (w/v) ascorbate salt (e.g., sodium ascorbate), wherein the radiopharmaceutical composition retains a radiochemical purity of the desired radiopharmaceutical of >90% over a period of at least 4 hours after radiosynthesis, and more preferably over a period of up to 8 hours after radiosynthesis.
- ascorbate salt e.g., sodium ascorbate
- the radiopharmaceutical composition of certain embodiments includes ethyl alcohol in a concentration range of about 1.0% to about 15.0% (v/v) and ascorbate salt (e.g., sodium ascorbate or other salt of ascorbic acid) in a concentration range of about 0.1% to about 1.0% (w/v).
- sodium ascorbate is used at a concentration of 0.5% (w/v).
- the pH of the composition can range from about 4.5 to about 8.0.
- the purity of the radiopharmaceutical is at least 90% when measured at least about 2 hours post end-of-synthesis (EOS). In preferred embodiments, the purity of the radiopharmaceutical composition is at least 90% when measured at least about 4 hours post EOS.
- a method for producing an 18 F-radiolabeled composition capable of binding to ⁇ -amyloid including synthesizing a tosylate precursor; performing nucleophilic 18 F fluorination of the tosylate precursor; formulating the 18 F fluorinated tosylate precursor in an aqueous solution; adding ethyl alcohol to achieve a minimum concentration of about 1.0% (w/v) in the final 18 F-
- a method of producing the tosylate precursor of 18 F- AV-45, (/i)-2-(2-(2-(5-(4-(te ⁇ 7-butoxycarbonyl(methyl)amino)slyryl)pyridin-2-yloxy)ethoxy) elhoxy)ethyl 4-methylbenzenesulfonate (“AV- 105") is provided.
- This method includes the
- a method of producing a radiopharmaceutical composition including reacting the AV-105 tosylate
- the method of producing the radiopharmaceutical composition may further include the step of formulating the ls F-AV-45 in a solution containing about 1.0% to about 15% (v/v) of ethyl 0 alcohol and about 0.1% to about 1.0% or more (w/v) of sodium ascorbate or other ascorbate salt.
- the sodium ascorbate concentration is 0.5% (w/v).
- a radiopharmaceutical composition comprising an effective amount of an l8 F-radiolabeled compound, at least about 1.0% (v/v) of ethyl alcohol, and at least about 0.1% (w/v) sodium ascorbate, wherein the radiopharmaceutical composition decomposes at a rate measured in vitro that substantially corresponds to the following: (a) from about 0.01 to about 5% of the total decomposition after about 2 hours of measurement; (b) from about 0.01 to about 10% of the total decomposition after about 10 hours of measurement; (c) from about 0.01 to about 20% of the total decomposition after about 15 hours of measurement; and (d) not more than about 25% of the total decomposition after about 24 hours of measurement.
- the invention involves synthesis methods for an 18 F- radiolabeled slyrylpyridine tosylate precursor, AV-105 (shown in FlG. 1).
- the AV-105 synthesis method utilizes a primary tosylate instead of a primary mesylate as an active leaving group.
- Use of the tosylate precursor for radiofluorination is beneficial, at least for the reason that the tosylate generated during the radiofluorination reaction is readily removed by chromatographic means from the 18 F-radiolabeled imaging product.
- FIG. 1 depicts an initial synthesis of AV-105 and a synthesis of cold AV-45 in one embodiment of the invention.
- /Moluenesulfonate (tosylate) as an active leading group eliminates the need for methansulfonate (mesylate), which is not preferred due to genotoxic properties of methane sulfonic acid, a side product formed when mesylate is utilized. Further, /Moluenesulfonic acid is more readily detected than methane sulfonic acid and therefore, can be purified more easily using liquid chromatography with UV detection. As further shown in FIG. 1, 4- dimethylaminopyridine (DMAP) is included in the Boc protection step (6 to 7) and the tosylation step (8) to produce AV-105.
- DMAP 4- dimethylaminopyridine
- FIG. 2 An alternative synthesis method for AV-105 is illustrated in FIG. 2.
- This convergent synthesis method uses /Moliienesulfonyl chloride rather than the typical methanesulfonyl chloride to generate a pseudo-halide.
- the use of the Heck reaction as shown in FIG. 2 increases the convergency of synthesis, thereby making the synthesis more efficient and leading to higher yields.
- the yields reported in FIGS. 1 and 2 are for illustrative purposes only and do not represent maximum obtainable yields.
- the synthetic methods for producing AV-105 described herein may be further optimized by use of purification techniques applied to the intermediate reactants or the AV- 105 itself. Such techniques may include, for example, recrystallization,
- the saline solution comprises at least about 1.0% (v/v) of ethyl alcohol and at least about 0.1 % (w/v) sodium ascorbate and has a pH between 4.5 and 8.0.
- the ethyl alcohol concentration is in the range of about 1.0% to about 10.0% (v/v) and the sodium ascorbaie concentration is in the range of about 0.1% to about 1.0% (w/v).
- the presence of sodium ascorbate minimizes radiolysis during the purification of crude 18 F-A V-45 and in the final product diluent to increase stability and shelf life.
- the nominal concentration of sodium ascorbate is 0.5% (w/v).
- a method for detecting a neurodegenerative disease in a patient including administering a radiopharmaceutical composition capable of binding to a target associated with a neurodegenerative disease comprising an effective amount of an " ⁇ -radiolabeled amyloid imaging compound, such as IR F-AV-45, or an alternative F-18 labeled amyloid binding radiopharmaceutical, with about 1.0% to 15% (v/v) of ethyl alcohol, and about 0.1% to 1% (w/v) of sodium ascorbate to the patient; imaging a portion of the patient comprising a region of the patient wherein the target is expected to be positioned; and detecting the target.
- the region of the patient may include at least a portion of the brain.
- the radiopharmaceutical composition can be used in the diagnosis of neurodegenerative disease such as, for example, dementia, cognitive impairment, Alzheimer's Disease (AD), Parkinson's Disease (PD), Dementia with Lewy Bodies (DLB), Vascular Dementia (VaD), and combinations thereof.
- the l8 F-radiolabeled pharmaceutical composition of embodiments of the present invention may be administered by any method known in the art.
- the radiopharmaceutical composition may be administrated by injection.
- methods of administration may include, but are not limited to, intravascular injection, intravenous injection, intraperitoneal injection, subcutaneous injection, and intramuscular injection
- the ls F-radiolabeIed pharmaceutical composition may also be administered in unit dosage form, e.g., as an intravenous administration.
- the radiopharmaceutical composition may be prepared in a unit dose syringe containing an appropriate quantity of the radiopharmaceutical.
- the IX F-radiolabeled pharmaceuticals of various embodiments of the invention may be imaged using any suitable technique known in the art including Positron Emission Tomography (PET). Single Photon Emission Computed Tomography (SPECT), PET with concurrent computed tomography imaging (PET/CT), PET with concurrent magnetic resonance imaging (PET/MRI) or a combination thereof.
- PET Positron Emission Tomography
- SPECT Single Photon Emission Computed Tomography
- PET/CT concurrent computed tomography imaging
- PET/MRI PET with concurrent magnetic resonance imaging
- the ' ⁇ -radiopharmaceutical compositions of embodiments of the invention possess both high radiochemical purity and high radiosynthetic yield.
- the shelf-lives of the i8 F-radiolabeled pharmaceuticals may vary among embodiments and may depend upon various aspects of the procedure. Generally, the shelf-lives of the 18 F-radiolabeled pharmaceuticals are greater 8 hours after production when formulated in the compositions described herein.
- Certain embodiments of the invention further provide a formulation of the ls F-labeled compound that is both safe for administration to humans and stable to radiolysis or other chemical degradation over the time period (e.g., up to 8- 10 hours) of shipment to hospitals or other imaging centers.
- an '"F-AV-45 radiopharmaceutical composition comprising ethyl alcohol and sodium ascorbaie maintains stability (greater than 90% RCP) for up to 20 hours post-production
- Example 1.0 Synthesis of AV-105 Tosylate Precursor to 18 F-A V-45.
- Mono-Boc- piotected vinylaniline 10 was prepared by vigorously stirring vinylaniline with di-/e ⁇ v-butyl dicarbonate in water at room temperature for 2 hours. Mono-Boc-protected vinylaniline 10 was precipitated and filtered to provide a 98% yield, which was used without further purification. Mcthylation of the intermediate using sodium hydride and methyl iodide in dimethylformamide (DMF) gave crude product lert-Buly ⁇ melhyl(4-vinylphenyl)carbamafe 11 (88% yield), which was also used without further purification. 2-Bromo-5-iodopyridine was alkylated with triethylene glycol using potassium /m-butoxide.
- Tosylation of the styrylpyridine 14 was performed using tosyl chloride, triethylamine, and DMAP in DCM to obtain AV- 105, which was purified using Biotage medium pressure flash chromatography. The overall yield starting from 2-bromo-5- iodopyridine was 40% (3 steps).
- the 18 F-A V -45 was then loaded onto a semi-preparative HPLC column and subjected to purification
- the HPLC fraction containing the purified !x F-AV-45 was collected in a reservoir containing 20 mL of WFI containing 0.5% w/v sodium ascorbaie.
- the diluted solution was passed through a SEP- PAKSKs C- 18 cartridge and the trapped 18 F-A V-45 was washed with 15 mL of WFl containing 0.5% w/v sodium ascorbate.
- the l8 F-AV-45 was eluted olT the SEP-PAK* Light C- 18 cartridge using I mL of EtOH (USP) into 9 mL of 0.9% Sodium Chloride Injection (sterile, USP) containing 0.5% w v sodium ascorbate (USP). This solution was then dispensed through a 0.22 ⁇ m sterilizing filter into a 10 or 30 mL sterile pre-crimped septum-sealed container.
- the lx F-AV-45 drug product may be diluted with Sodium Chloride Injection (0.9%, USP, sterile) containing NMT 10% v/v EtOH (USP) and 0.5% w/v sodium ascorbate (USP).
- Example 3.0 Formulation for Solubilization of 19 F-A V-45 and Stabilization of 18 F-AV- 45.
- 0068] The ls F-AV-45 radiopharmaceutical formulation/composition was evaluated for the solubility of the non-radioactive 19 F-A V-45. which is also formed in quantities of 1-5 ⁇ g/mL during the radiosynthesis of lx F-AV-45 due to the presence of small quantities of ⁇ y F- fluoride from tubing, valves and other sources in the radiosynthesis system. In the absence of ethanol in the composition, particulate matter may be observed due to the low solubility of V ')" 1 F-AV -45.
- the addition of 10% ethanol to the radiopharmaceutical composition was, therefore, evaluated to determine if the solubility of 19 F-A V-45 was sufficient to avoid the potential of precipitate formation.
- the solubility limit of AV-45 in the drug product composition (10% (v/v) EtOH and 0.5% (w/v) sodium ascorbate in 0.9% aqueous sodium chloride) was determined to be 17 ⁇ g/mL at ambient temperature. A visible precipitate was noticeable in solutions with concentrations > 22 ⁇ g/mL. Samples prepared at concentrations ⁇ 20 ⁇ g/mL were evaluated by HPLC analysis following centrifugation. Samples with ⁇ 20 ⁇ g/mL were also tested after storage for one week at ambient temperature.
- the li! F- ⁇ V-45 radiopharmaceutical compositions of embodiments of the invention are remarkably stable to radiolysis or chemical degradation.
- Sodium ascorbate is used to minimize radiolysis during the purification of 18 F-A V-45 and in the final drug product solution to increase stability and shelf life.
- Ethanol at 1- 10% (v/v) in aqueous solution aids in the solubilization of ls F-AV-45.
- research compositions were manufactured with and without sodium ascorbate.
- compositions were analyzed at end-of-synthesis (EOS) using reverse HPLC, equipped with both an ultra violet (UV) detector and radiochemical detector
- EOS end-of-synthesis
- UV ultra violet
- radiochemical purity of ls F-AV-45 was monitored by HPLC with radiometric detection and the purity of 19 F-AV- 45 was monitored by HPLC UV detection in the drug product by Area Percent Normalization.
- the area percent values for both radiochemical and ultraviolet analysis are shown in Tables 1 and 2.
- the radiochemical purity of the 18 F-A V-45 composition prepared without sodium ascorbaie was 84% and decomposed further such that at 2 hours the purity was 80%.
- the purity of the 18 F-A V-45 composition manufactured with sodium ascorbate was significantly higher.
- the purity was 96% with negligible decomposition at 2 hours post EOS (purity of 95%).
Abstract
Description
Claims
Priority Applications (23)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2011007063A MX2011007063A (en) | 2008-12-31 | 2009-12-29 | Synthesis of 18f-radiolabeled styrylpyridines from tosylate precursors and stable pharmaceutical compositions thereof. |
ES09837135.4T ES2620402T3 (en) | 2008-12-31 | 2009-12-29 | Synthesis of radiolabeled styrylpyridines with 18F from tosylate precursors and stable pharmaceutical compositions thereof |
CA2748705A CA2748705C (en) | 2008-12-31 | 2009-12-29 | Synthesis of 18f-radiolabeled styrylpyridines from tosylate precursors and stable pharmaceutical compositions thereof |
JP2011543721A JP5717650B2 (en) | 2008-12-31 | 2009-12-29 | Synthesis of 18F-radiolabeled styrylpyridine and its stable pharmaceutical composition from tosylate precursor |
EP09837135.4A EP2381967B1 (en) | 2008-12-31 | 2009-12-29 | Synthesis of 18f-radiolabeled styrylpyridines from tosylate precursors and stable pharmaceutical compositions thereof |
AU2009335049A AU2009335049B2 (en) | 2008-12-31 | 2009-12-29 | Synthesis of 18F-radiolabeled styrylpyridines from tosylate precursors and stable pharmaceutical compositions thereof |
UAA201109307A UA105914C2 (en) | 2008-12-31 | 2009-12-29 | Synthesis of 18f-radiolabeled styrylpyridines from tosylate precursors and stable pharmaceutical compositions thereof |
CN200980153414.5A CN102271716B (en) | 2008-12-31 | 2009-12-29 | Synthesis of 18f-radiolabeled styrylpyridines from tosylate precursors and stable pharmaceutical compositions thereof |
BRPI0923890-5A BRPI0923890A2 (en) | 2008-12-31 | 2009-12-29 | Synthesis of radiolabeled 18f-stylpyridines from tosylate percussors of stable pharmaceutical compositions thereof. |
SG2011048055A SG172439A1 (en) | 2008-12-31 | 2009-12-29 | Synthesis of 18f-radiolabeled styrylpyridines from tosylate precursors and stable pharmaceutical compositions thereof |
SI200931600A SI2381967T1 (en) | 2008-12-31 | 2009-12-29 | Synthesis of 18f-radiolabeled styrylpyridines from tosylate precursors and stable pharmaceutical compositions thereof |
NZ593848A NZ593848A (en) | 2008-12-31 | 2009-12-29 | Synthesis of 18f-radiolabeled styrylpyridines from tosylate precursors and stable pharmaceutical compositions thereof |
DK09837135.4T DK2381967T3 (en) | 2008-12-31 | 2009-12-29 | Synthesis of 18F-radiolabelled styryl pyridines from tosylate precursors and stable pharmaceutical compositions thereof |
RS20170117A RS55674B1 (en) | 2008-12-31 | 2009-12-29 | Synthesis of 18f-radiolabeled styrylpyridines from tosylate precursors and stable pharmaceutical compositions thereof |
MA34065A MA33004B1 (en) | 2008-12-31 | 2009-12-29 | SYNTHESIS OF 18F-RADIOMARQUE STYRYLPYRIDINES FROM TOSYLATE PRECURSORS AND THEIR STABLE PHARMACEUTICAL COMPOSITIONS |
EA201170911A EA023014B1 (en) | 2008-12-31 | 2009-12-29 | Synthesis of 18f-radiolabeled styrylpyridines from tosylate precursors and stable pharmaceutical compositions thereof |
LTEP09837135.4T LT2381967T (en) | 2008-12-31 | 2009-12-29 | Synthesis of 18f-radiolabeled styrylpyridines from tosylate precursors and stable pharmaceutical compositions thereof |
IL213674A IL213674A (en) | 2008-12-31 | 2011-06-20 | Synthesis of 18f radiolabeled styrylpyridines from tosylate precursors and stable pharmaceutical compositions thereof |
TN2011000318A TN2011000318A1 (en) | 2008-12-31 | 2011-06-24 | Synthesis of 18f-radiolabeled strylpyridines from tosylate precursors and stable pharmaceutical compositions thereof |
ZA2011/04824A ZA201104824B (en) | 2008-12-31 | 2011-06-29 | Synthesis of 18f-radiolabeled styrylpyridines from tosylate precursors and stable pharmaceutical compositions thereof |
HK12103613.7A HK1162951A1 (en) | 2008-12-31 | 2012-04-12 | Synthesis of 18f-radiolabeled styrylpyridines from tosylate precursors and stable pharmaceutical compositions thereof 18f- |
CY20171100253T CY1118658T1 (en) | 2008-12-31 | 2017-02-24 | COMPOSITION OF 18F-RADIATED STYLYLPYRIDINES FROM TOYULIC PRECISIONS COMPOUNDS AND STABLE PHARMACEUTICAL COMPOSITIONS |
HRP20170453TT HRP20170453T1 (en) | 2008-12-31 | 2017-03-20 | Synthesis of 18f-radiolabeled styrylpyridines from tosylate precursors and stable pharmaceutical compositions thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14188508P | 2008-12-31 | 2008-12-31 | |
US61/141,885 | 2008-12-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010078370A1 true WO2010078370A1 (en) | 2010-07-08 |
Family
ID=42310197
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/069741 WO2010078370A1 (en) | 2008-12-31 | 2009-12-29 | Synthesis of 18f-radiolabeled styrylpyridines from tosylate precursors and stable pharmaceutical compositions thereof |
Country Status (36)
Country | Link |
---|---|
US (1) | US20100172836A1 (en) |
EP (1) | EP2381967B1 (en) |
JP (1) | JP5717650B2 (en) |
KR (1) | KR20110119670A (en) |
CN (1) | CN102271716B (en) |
AU (1) | AU2009335049B2 (en) |
BR (1) | BRPI0923890A2 (en) |
CA (1) | CA2748705C (en) |
CO (1) | CO6341578A2 (en) |
CR (1) | CR20110410A (en) |
CY (1) | CY1118658T1 (en) |
DK (1) | DK2381967T3 (en) |
DO (1) | DOP2011000210A (en) |
EA (1) | EA023014B1 (en) |
EC (1) | ECSP11011242A (en) |
ES (1) | ES2620402T3 (en) |
HK (1) | HK1162951A1 (en) |
HN (1) | HN2011001810A (en) |
HR (1) | HRP20170453T1 (en) |
HU (1) | HUE033649T2 (en) |
IL (1) | IL213674A (en) |
LT (1) | LT2381967T (en) |
MA (1) | MA33004B1 (en) |
MX (1) | MX2011007063A (en) |
MY (1) | MY162312A (en) |
NZ (1) | NZ593848A (en) |
PE (1) | PE20120007A1 (en) |
PL (1) | PL2381967T3 (en) |
PT (1) | PT2381967T (en) |
RS (1) | RS55674B1 (en) |
SG (1) | SG172439A1 (en) |
SI (1) | SI2381967T1 (en) |
TN (1) | TN2011000318A1 (en) |
UA (1) | UA105914C2 (en) |
WO (1) | WO2010078370A1 (en) |
ZA (1) | ZA201104824B (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011151273A1 (en) | 2010-06-04 | 2011-12-08 | Bayer Pharma Aktiengesellschaft | Method for production of f-18 labeled amyloid beta ligands |
WO2011151282A1 (en) | 2010-06-04 | 2011-12-08 | Bayer Pharma Aktiengesellschaft | Method for production of f-18 labeled amyloid beta ligand |
WO2011151283A1 (en) | 2010-06-04 | 2011-12-08 | Bayer Pharma Aktiengesellschaft | Method for production of f-18 labeled amyloid beta ligands |
WO2012145169A3 (en) * | 2011-04-21 | 2013-03-14 | The Regents Of The University Of California | Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles |
WO2013057199A1 (en) | 2011-10-19 | 2013-04-25 | Piramal Imaging Sa | IMPROVED METHOD FOR PRODUCTION OF F-18 LABELED Aß LIGANDS |
US20180028695A1 (en) * | 2016-07-26 | 2018-02-01 | Laboratoires Cyclopharma | Synthesis of a radioactive agent composition |
WO2019145293A1 (en) * | 2018-01-24 | 2019-08-01 | Ac Immune Sa | Diagnostic compositions for pet imaging, a method for manufacturing the diagnostic composition and its use in diagnostics |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2910945B1 (en) * | 2008-09-30 | 2018-07-18 | Case Western Reserve University | Molecular probes for imaging of myelin |
MX344954B (en) * | 2011-06-21 | 2017-01-12 | Piramal Imaging Sa | Formulations of fluorinated stilbene suitable for pet imaging. |
CN102432529B (en) * | 2011-11-14 | 2014-03-26 | 江苏省原子医学研究所 | Preparation method of styryl pyridine disulfide dinitrogen derivative |
WO2013090497A1 (en) * | 2011-12-15 | 2013-06-20 | Ge Healthcare Limited | Heterocyclic compounds as imaging probes of tau pathology |
CN102526765B (en) * | 2011-12-31 | 2014-07-30 | 郑州泰基鸿诺药物科技有限公司 | Abeta plaque developing agent and preparation method thereof |
CN103965105A (en) * | 2013-01-29 | 2014-08-06 | 中山大学 | Styryl quinoline derivative and application thereof to treatment of Alzheimer disease |
CN103645254B (en) * | 2013-11-28 | 2015-01-07 | 江苏省原子医学研究所 | Method for analyzing content of A beta plaque developer precursor AV45 |
WO2017014599A1 (en) * | 2015-07-22 | 2017-01-26 | 주식회사 씨코헬스케어 | Composition for stabilizing radiochemical purity of [18f]fluoro-dopa and method for preparing same |
CA3003884C (en) * | 2015-11-13 | 2020-04-21 | Eli Lilly And Company | Azetidine derivatives for tau imaging |
US10765763B2 (en) | 2016-03-09 | 2020-09-08 | Case Western Reserve University | Radioligands for myelin |
CN107198780A (en) * | 2016-03-18 | 2017-09-26 | 南京江原安迪科正电子研究发展有限公司 | Radiopharmaceutical composition and preparation method thereof, application |
CN106018575B (en) * | 2016-05-05 | 2018-10-19 | 江苏省原子医学研究所 | A kind of method of separating and assaying of PET imaging agent precursors TsOP- (+)-DTBZ and its optical isomer |
EP3538161B1 (en) * | 2016-11-08 | 2022-07-27 | The Regents of The University of California | Methods for multi-dose synthesis of [f-18]fddnp for clinical settings |
TW201906818A (en) * | 2017-05-31 | 2019-02-16 | 美商511製藥公司 | Novel erbium-substituted positron emission tomography (PET) developer and its pharmacological application |
CN111499544B (en) * | 2019-01-31 | 2022-12-02 | 中国医学科学院放射医学研究所 | Synthetic method for preparing N-Boc-N-methyl-4-aminostyrene by one-pot method |
CN111499570B (en) * | 2019-01-31 | 2023-05-16 | 中国医学科学院放射医学研究所 | Synthesis method of AV-45 intermediate |
WO2020202831A1 (en) * | 2019-03-29 | 2020-10-08 | 国立研究開発法人量子科学技術研究開発機構 | Method for producing radiopharmaceutical and radiopharmaceutical |
CN115403434A (en) * | 2021-05-26 | 2022-11-29 | 汉中汉核医疗科技有限公司 | Synthetic method of radiopharmaceutical |
CN115400232A (en) * | 2021-05-26 | 2022-11-29 | 汉中汉核医疗科技有限公司 | Method for synthesizing radiopharmaceutical |
CN113582885B (en) * | 2021-08-30 | 2023-04-21 | 南京克米斯璀新能源科技有限公司 | Production method of sodium alkyl sulfonate |
CN114805190A (en) * | 2022-06-08 | 2022-07-29 | 吉林大学第一医院 | Double-column synthesis method of methylaniline Abeta protein developer |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070281299A1 (en) * | 2004-01-19 | 2007-12-06 | Youdim Moussa B | Diagnostic Test For Parkinson's Disease |
US20080038195A1 (en) * | 2006-03-30 | 2008-02-14 | The Trustees Of The University Of Pennsylvania | Stryrylpyridine derivates and theur use for binding and imaging amylod plaques |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2213652T1 (en) * | 2004-12-17 | 2015-03-31 | The Trustees Of The University Of Pennsylvania | Stilbene derivatives and their use for binding and imaging amyloid plaques |
-
2009
- 2009-12-29 MA MA34065A patent/MA33004B1/en unknown
- 2009-12-29 PT PT98371354T patent/PT2381967T/en unknown
- 2009-12-29 RS RS20170117A patent/RS55674B1/en unknown
- 2009-12-29 EP EP09837135.4A patent/EP2381967B1/en active Active
- 2009-12-29 NZ NZ593848A patent/NZ593848A/en unknown
- 2009-12-29 KR KR1020117017636A patent/KR20110119670A/en not_active Application Discontinuation
- 2009-12-29 CN CN200980153414.5A patent/CN102271716B/en active Active
- 2009-12-29 BR BRPI0923890-5A patent/BRPI0923890A2/en active Search and Examination
- 2009-12-29 PE PE2011001294A patent/PE20120007A1/en not_active Application Discontinuation
- 2009-12-29 SI SI200931600A patent/SI2381967T1/en unknown
- 2009-12-29 EA EA201170911A patent/EA023014B1/en not_active IP Right Cessation
- 2009-12-29 DK DK09837135.4T patent/DK2381967T3/en active
- 2009-12-29 JP JP2011543721A patent/JP5717650B2/en active Active
- 2009-12-29 CA CA2748705A patent/CA2748705C/en active Active
- 2009-12-29 PL PL09837135T patent/PL2381967T3/en unknown
- 2009-12-29 HU HUE09837135A patent/HUE033649T2/en unknown
- 2009-12-29 ES ES09837135.4T patent/ES2620402T3/en active Active
- 2009-12-29 LT LTEP09837135.4T patent/LT2381967T/en unknown
- 2009-12-29 SG SG2011048055A patent/SG172439A1/en unknown
- 2009-12-29 MY MYPI2011003056A patent/MY162312A/en unknown
- 2009-12-29 UA UAA201109307A patent/UA105914C2/en unknown
- 2009-12-29 US US12/648,869 patent/US20100172836A1/en not_active Abandoned
- 2009-12-29 MX MX2011007063A patent/MX2011007063A/en active IP Right Grant
- 2009-12-29 AU AU2009335049A patent/AU2009335049B2/en active Active
- 2009-12-29 WO PCT/US2009/069741 patent/WO2010078370A1/en active Application Filing
-
2011
- 2011-06-20 IL IL213674A patent/IL213674A/en active IP Right Grant
- 2011-06-24 TN TN2011000318A patent/TN2011000318A1/en unknown
- 2011-06-29 DO DO2011000210A patent/DOP2011000210A/en unknown
- 2011-06-29 HN HN2011001810A patent/HN2011001810A/en unknown
- 2011-06-29 ZA ZA2011/04824A patent/ZA201104824B/en unknown
- 2011-07-11 CO CO11086470A patent/CO6341578A2/en active IP Right Grant
- 2011-07-29 CR CR20110410A patent/CR20110410A/en unknown
- 2011-07-29 EC EC2011011242A patent/ECSP11011242A/en unknown
-
2012
- 2012-04-12 HK HK12103613.7A patent/HK1162951A1/en not_active IP Right Cessation
-
2017
- 2017-02-24 CY CY20171100253T patent/CY1118658T1/en unknown
- 2017-03-20 HR HRP20170453TT patent/HRP20170453T1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070281299A1 (en) * | 2004-01-19 | 2007-12-06 | Youdim Moussa B | Diagnostic Test For Parkinson's Disease |
US20080038195A1 (en) * | 2006-03-30 | 2008-02-14 | The Trustees Of The University Of Pennsylvania | Stryrylpyridine derivates and theur use for binding and imaging amylod plaques |
Non-Patent Citations (10)
Title |
---|
CHOI, SR ET AL., JNUCL MED, vol. 50, no. 1 1, 2009, pages 1887 - 1894 |
FIRNAU G ET AL., J NUCL MED, vol. 25, 1984, pages 1228 - 1233 |
KNAPP FF ET AL., ANTICANCER RES, vol. 17, 1997, pages 1783 - 1795 |
LEMAIRE C. ET AL., J LABEL COMPD AND RADIOPHARM, vol. 42, 1999, pages 63 - 75 |
LIU S ET AL., BIOCONJ CHEM, vol. 14, 2003, pages 1052 - 1056 |
See also references of EP2381967A4 |
SOUZA ET AL.: "Longitudinal noninvasive PET-based Beta cell mass estimates in a spontaneous diabetes rat model.", JOURNAL OF CLINICAL INVESTIGATION, vol. 116, June 2006 (2006-06-01), pages 1506 - 1513 * |
TOFE AJ ET AL., J. NUCL MED, vol. 17, 1976, pages 820 - 825 |
ZHANG ET AL.: "F-18 Stilbenes as PET Imaging Agents for Detecting Beta-Amyloid Plaques in the Brain.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 48, 2005, pages 5980 - 5988, XP008127167, DOI: doi:10.1021/jm050166g * |
ZHANG W ET AL., NUCL MED BIOL, vol. 34, 2007, pages 89 - 97 |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011151282A1 (en) | 2010-06-04 | 2011-12-08 | Bayer Pharma Aktiengesellschaft | Method for production of f-18 labeled amyloid beta ligand |
WO2011151283A1 (en) | 2010-06-04 | 2011-12-08 | Bayer Pharma Aktiengesellschaft | Method for production of f-18 labeled amyloid beta ligands |
WO2011151273A1 (en) | 2010-06-04 | 2011-12-08 | Bayer Pharma Aktiengesellschaft | Method for production of f-18 labeled amyloid beta ligands |
EA025823B1 (en) * | 2010-06-04 | 2017-02-28 | Пирамаль Имэджинг Са | Method for production of f-18 labeled amyloid beta ligands |
US10232059B2 (en) | 2011-04-21 | 2019-03-19 | The Regents Of The University Of California | Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles |
WO2012145169A3 (en) * | 2011-04-21 | 2013-03-14 | The Regents Of The University Of California | Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles |
CN103491870A (en) * | 2011-04-21 | 2014-01-01 | 加利福尼亚大学董事会 | Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles |
US9272055B2 (en) | 2011-04-21 | 2016-03-01 | The Regents Of The University Of California | Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles |
CN103491870B (en) * | 2011-04-21 | 2016-12-28 | 加利福尼亚大学董事会 | Functionalized magnetic nanoparticles and in amyloid deposition and neurofibrillary tangles imaging purposes |
US10751428B2 (en) | 2011-04-21 | 2020-08-25 | The Regents Of The University Of California | Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles |
WO2013057199A1 (en) | 2011-10-19 | 2013-04-25 | Piramal Imaging Sa | IMPROVED METHOD FOR PRODUCTION OF F-18 LABELED Aß LIGANDS |
US10695450B2 (en) * | 2016-07-26 | 2020-06-30 | Laboratoires Cyclopharma | Synthesis of a radioactive agent composition |
US20180028695A1 (en) * | 2016-07-26 | 2018-02-01 | Laboratoires Cyclopharma | Synthesis of a radioactive agent composition |
WO2019145293A1 (en) * | 2018-01-24 | 2019-08-01 | Ac Immune Sa | Diagnostic compositions for pet imaging, a method for manufacturing the diagnostic composition and its use in diagnostics |
CN111712265A (en) * | 2018-01-24 | 2020-09-25 | Ac免疫有限公司 | Diagnostic composition for PET imaging, method for the preparation thereof and use thereof in diagnostics |
CN111712265B (en) * | 2018-01-24 | 2024-02-09 | Ac免疫有限公司 | Diagnostic composition for PET imaging, method for producing the same and use thereof in diagnosis |
IL275990B1 (en) * | 2018-01-24 | 2024-04-01 | Ac Immune Sa | Diagnostic compositions for pet imaging, a method for manufacturing the diagnostic composition and its use in diagnostics |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2009335049B2 (en) | Synthesis of 18F-radiolabeled styrylpyridines from tosylate precursors and stable pharmaceutical compositions thereof | |
JP2019218371A (en) | Compositions, methods and systems for synthesis and use of imaging agents | |
US20080219922A1 (en) | Alzheimer's Disease Imaging Agents | |
EP2218464A1 (en) | Compounds for non-invasive measurement of aggregates of amyloid peptides | |
AU2014338155B2 (en) | Tau imaging probe | |
AU2011329311A1 (en) | Heterocyclic compounds as imaging probes of Tau pathology | |
JP7260552B2 (en) | Diagnostic compositions for PET imaging, methods for making diagnostic compositions and their use in diagnostics | |
US20160263258A1 (en) | Radiotracer introduced [18F]fluoromethyl group targeting neuroinflammation for PET imaging and Synthesis of Radiotracer and its biological evaluation Method for Radiotracer | |
Watanabe et al. | Synthesis and biological evaluation of 123 I-labeled pyridyl benzoxazole derivatives: novel β-amyloid imaging probes for single-photon emission computed tomography | |
AU2019212170B2 (en) | Novel method of preparing an imaging compound | |
WO2010135493A2 (en) | Alzheimer's disease imaging agents | |
US20220024896A1 (en) | Tau pet imaging ligands | |
EP3835293A1 (en) | Monoamine oxidase b imaging probe | |
JP2021102593A (en) | New compound imaging tau | |
JPWO2014132919A1 (en) | Diagnostic composition | |
WO2012175702A1 (en) | Rimfampicin analogue useful for infection imaging | |
MICAD Research Team | [123I/125I] 6-Iodo-2-(4´-dimethylamino)-phenyl-imidazo [1, 2-a] pyridine | |
CA3026999A1 (en) | Tau pet imaging ligands |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980153414.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09837135 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2011543721 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009335049 Country of ref document: AU Ref document number: 001294-2011 Country of ref document: PE |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2011/007063 Country of ref document: MX Ref document number: 12011501341 Country of ref document: PH |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2748705 Country of ref document: CA Ref document number: 593848 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5130/DELNP/2011 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11086470 Country of ref document: CO |
|
ENP | Entry into the national phase |
Ref document number: 2009335049 Country of ref document: AU Date of ref document: 20091229 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: DZP2011000507 Country of ref document: DZ |
|
REEP | Request for entry into the european phase |
Ref document number: 2009837135 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009837135 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20117017636 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2011-000410 Country of ref document: CR Ref document number: 201170911 Country of ref document: EA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI0923890 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: PI0923890 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110630 |
|
WWE | Wipo information: entry into national phase |
Ref document number: P-2017/0117 Country of ref document: RS |